Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs
Science · 06.12.2024 · 386 (6726)
DOI: 10.1126/science.adl4793 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 06.12.2024. Verfasst von Nishith R Reddy und 13 weiteren Autor:innen. Beteiligte Einrichtung: UCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Cell Engineering, Receptors, Chimeric Antigen, Immunosuppression Therapy. Die Arbeit wurde bisher 65-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4 + T cells with synthetic Notch (synNotch) receptors driving antigen-triggered production of anti-inflammatory payloads. Screening a diverse library of suppression programs, we observed the strongest suppression of cytotoxic T cell attack by the production of both anti-inflammatory factors (interleukin-10, transforming growth factor–β1, programmed death ligand 1) and sinks for proinflammatory cytokines (interleukin-2 receptor subunit CD25). Engineered cells with bespoke regulatory programs protected tissues from immune attack without systemic suppression. Synthetic suppressor T cells protected transplanted beta cell organoids from cytotoxic T cells. They also protected specific tissues from unwanted chimeric antigen receptor (CAR) T cell cross-reaction. Synthetic suppressor T cells are a customizable platform to potentially treat autoimmune diseases, organ rejection, and CAR T cell toxicities with spatial precision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- UCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.
- Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA, USA.
- Diabetes Center, University of California, San Francisco, San Francisco, CA, USA.
- Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA.
- UCSF CoLabs, University of California, San Francisco, San Francisco, CA, USA.
- Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA, USA.
ORCID-Profile: Nishith R Reddy, Hasna Maachi, Yini Xiao, Milos S Simic, Wei Yu, Yurie Tonai, Daniela A Cabanillas, Ella Serrano-Wu, Philip T Pauerstein, Whitney Tamaki, Greg M Allen, Audrey V Parent, Matthias Hebrok, Wendell A Lim
Förderung
- NIDDK NIH HHS
- NCI NIH HHS
Zitieren
APA
Reddy, N. R., Maachi, H., Xiao, Y., Simic, M. S., Yu, W., Tonai, Y., Cabanillas, D. A., Serrano-Wu, E., Pauerstein, P. T., Tamaki, W., Allen, G. M., Parent, A. V., Hebrok, M., & Lim, W. A. (2024). Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science, 386(6726). https://doi.org/10.1126/science.adl4793
Vancouver
Reddy NR, Maachi H, Xiao Y, Simic MS, Yu W, Tonai Y, et al. Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science. 2024;386(6726). doi:10.1126/science.adl4793
BibTeX
@article{Reddy2024,
author = {Reddy, Nishith R and Maachi, Hasna and Xiao, Yini and Simic, Milos S and Yu, Wei and Tonai, Yurie and Cabanillas, Daniela A and Serrano-Wu, Ella and Pauerstein, Philip T and Tamaki, Whitney and Allen, Greg M and Parent, Audrey V and Hebrok, Matthias and Lim, Wendell A},
title = {Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs},
journal = {Science},
year = {2024},
volume = {386},
number = {6726},
doi = {10.1126/science.adl4793}
}
EUVIMED